

Federal Deposit Insurance Corporation.  
**Robert E. Feldman,**  
*Executive Secretary.*  
 [FR Doc. E8-26830 Filed 11-10-08; 8:45 am]  
**BILLING CODE 6714-01-P**

## FEDERAL RESERVE SYSTEM

### Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at [www.ffiec.gov/nic/](http://www.ffiec.gov/nic/).

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than December 5, 2008.

**A. Federal Reserve Bank of St. Louis** (Glenda Wilson, Community Affairs Officer) P.O. Box 442, St. Louis, Missouri 63166-2034:

1. *Mt. Sterling Bancorp, Inc.*, Mt. Sterling, Illinois, to acquire 100 percent of the voting shares of Timewell State Bank, Timewell, Illinois.

**B. Federal Reserve Bank of Dallas** (E. Ann Worthy, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Big Country Bancshares, Inc.*, Abilene, Texas, to become a bank holding company by acquiring 100

percent of the voting shares of Citizens Bank, N.A., Abilene, Texas.

Board of Governors of the Federal Reserve System, November 6, 2008.

**Jennifer J. Johnson,**  
*Secretary of the Board.*

[FR Doc. E8-26808 Filed 11-10-08; 8:45 am]

**BILLING CODE 6210-01-S**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Board of Scientific Counselors, Coordinating Center for Infectious Diseases (CCID)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee:

#### *Times and Dates:*

9 a.m.-5 p.m., December 4, 2008.

8:30 a.m.-3:30 p.m., December 5, 2008.

*Place:* CDC, Global Conference Center, Building 19, 1600 Clifton Road, NE., Atlanta, Georgia 30333.

December 4, 2008—Building 19 (Work Groups meet).

December 5, 2008—Auditorium B3 (Full Board meets).

*Status:* Open to the public, limited only by the space available.

*Purpose:* The Board of Scientific Counselors, CCID, provides advice and guidance to the Director, CDC, and Director, CCID, in the following areas: program goals and objectives; strategies; program organization and resources for infectious disease prevention and control; and program priorities.

*Matters to be Discussed:* Agenda items will include:

1. *Breakout Group Discussions:* Vaccine Trust and Vaccine in Healthcare Workers (National Center for Preparedness, Detection, and Control of Infectious Diseases and National Center for Immunization and Respiratory Diseases). Discussion will be how reports, statements and recommendations of our established advisory committees (Advisory Council for the Elimination of Tuberculosis, CDC/HRSA Advisory Committee) can be presented to the Work Group and full committee most efficiently and effectively (National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, (NCHHSTP)). Program Collaboration and Service Integration (NCHHSTP) International Activities (National Center for Zoonotic, Vector-Borne, and Enteric Diseases, (NCZVED)). Peer Reviews and Planning and New Technology (NCZVED).

2. Antimicrobial Resistance (Full Board).

3. Budget and CCID/Office of the Director Updates (Full Board).

Other agenda items include announcements, introductions, and follow-

up on actions recommended by the board, directions, goals, and recommendations.

Agenda items are subject to change as priorities dictate.

Written comments are welcome and should be received by the contact person listed below prior to the opening of the meeting.

*Contact Person for More Information:*

Harriette Lynch, Office of the Director, CCID, CDC, Mailstop E-77, 1600 Clifton Road, NE., Atlanta, Georgia 30333, *Telephone:* (404)498-2726, *e-mail:* [hlynch@cdc.gov](mailto:hlynch@cdc.gov).

The Director, Management Analysis and Services office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the CDC and the Agency for Toxic Substances and Disease Registry.

Dated: November 4, 2008.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E8-26795 Filed 11-10-08; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Board of Scientific Counselors, National Center for Health Marketing (BSC, NCHM)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), CDC announces the following meeting of the aforementioned committee:

*Times and Dates:* 9 a.m.-4:30 p.m., December 8, 2008. 9 a.m.-3 p.m., December 9, 2008.

*Place:* CDC, Tom Harkin Global Communications Center, 1600 Clifton Road, NE., Building 21, Auditorium A (Room 1204A), Atlanta, Georgia 30333.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 60 people.

*Purpose:* The Secretary, Department of Health and Human Services (HHS), and, by delegation, the Director, Centers for Disease Control and Prevention (CDC), are authorized under Section 301 (42 U.S.C. 241) and Section 311 (42 U.S.C. 243) of the Public Health Service Act (PHSA), as amended to: develop and implement disease prevention and control, environmental health, and health promotion and health education activities designed to improve the health of the people of the United States. Under these and additional PHSA and other authorities, CDC acts by identifying and defining preventable health problems; maintaining active surveillance of diseases through epidemiologic and laboratory investigations and data collection, analysis, and distribution; conducting operational research aimed at developing and testing effective disease prevention, control, and health

promotion programs; administering a national occupational safety and health program; controlling the introduction and spread of infectious diseases; and providing consultation and assistance to other nations and international agencies to assist in improving their disease prevention and control, environmental health, and health promotion activities. CDC carries out these functions through a number of Coordinating Centers/Offices and National Centers and Institutes with expertise and responsibilities in specific areas.

**Matters to be Discussed:** The agenda will include discussions on program activities, including scientific programs, that will assist in consolidating and refining NCHM vision, mission, goals, organizational structure and expanding and implementing its science for the National Center for Health Marketing; and discussions related to the National Center's role in preparedness, response and recovery with regards to an outbreak of pandemic influenza

Agenda items are tentative and subject to change.

**Contact Person for More Information:** Dionne R. Mason, Committee Management Specialist, NCHM, 1600 Clifton Road, Mail Stop E-21, Atlanta, Georgia 30333, Telephone: (404) 498-2314, Fax (404) 498-2221. The deadline for notification of attendance is November 20, 2008.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: November 4, 2008.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. E8-26803 Filed 11-10-08; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention (CDC)

#### National Center for Injury Prevention and Control, Initial Review Group, (NCIPC, IRG)

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), CDC announces the following meeting for the aforementioned committee:

**Times and Date:** 1 p.m.-2:30 p.m., December 8, 2008 (Closed).

**Place:** Teleconference.

**Status:** The meeting will be closed to the public in accordance with provisions set forth in Section 552b(c)(4) and (6), Title 5, U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Section 10(d) of Public Law 92-463.

**Purpose:** This group is charged with providing advice and guidance to the Secretary, Department of Health and Human Services, and the Director, CDC, concerning the scientific and technical merit of grant and cooperative agreement applications received from academic institutions and other public and private profit and nonprofit organizations, including State and local government agencies, to conduct specific injury research that focuses on prevention and control.

**Matters to be Discussed:** The meeting will include the reporting and voting of the peer reviews conducted in response to Fiscal Year 2008 Requests for Applications related to the following individual research announcements: (1) RFA-CD-08-001, "Elimination of Health Disparities Through Translation Research (R18)" and (2) RFA-CE-09-001, "Grants for the Injury Control Research Centers". Agenda items are subject to change as priorities dictate.

**Contact Person for More Information:** Rick Waxweiler, PhD, Director, Extramural Research Program Office, NCIPC and Executive Secretary, NCIPC IRG, CDC, 4770 Buford Highway, NE., Mail Stop F-62, Atlanta, Georgia 30341, Telephone: (770) 488-4850.

The Director, Management Analysis and Services Office has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both CDC and the Agency for Toxic Substances and Disease Registry.

Dated: November 4, 2008.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. E8-26801 Filed 11-10-08; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2008-N-0345]

#### Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practices and Related Regulations for Blood and Blood Components; and Requirements for Donor Testing, Donor Notification, and "Lookback"

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

**DATES:** Fax written comments on the collection of information by December 12, 2008.

**ADDRESSES:** To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202-395-6974, or e-mailed to [oir\\_submission@omb.eop.gov](mailto:oir_submission@omb.eop.gov). All comments should be identified with the OMB control number 0910-0116. Also include the FDA docket number found in brackets in the heading of this document.

**FOR FURTHER INFORMATION CONTACT:** Jonna Capezzuto, Office of Information Management (HFA-710), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-796-3794.

**SUPPLEMENTARY INFORMATION:** In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

#### Current Good Manufacturing Practices and Related Regulations for Blood and Blood Components; and Requirements for Donor Testing, Donor Notification, and "Lookback" (OMB Control Number 0910-0116—Extension)

All blood and blood components introduced or delivered for introduction into interstate commerce are subject to section 351(a) of the Public Health Service Act (PHS Act) (42 U.S.C. 262). Section 351(a) requires that manufacturers of biological products, which include blood and blood components intended for further manufacture into injectable products, have a license, issued upon a demonstration that the product is safe, pure and potent and that the manufacturing establishment meets all applicable standards, including those prescribed in the FDA regulations designed to ensure the continued safety, purity, and potency of the product. In addition, under section 361 of the PHS Act (42 U.S.C. 264), by delegation from the Secretary of Health and Human Services, FDA may make and enforce regulations necessary to prevent the introduction, transmission, or spread of communicable diseases from foreign countries into the States or possessions, or from one State or possession into any other State or possession.

Section 351(j) of the PHS Act states that the Federal Food, Drug, and Cosmetic (FD&C) Act also applies to biological products. Blood and blood components for transfusion or for further manufacture into injectable products are drugs, as that term is